A 40 year old male patient is suffering from type II diabetes mellitus and hypeension. Which of the following antihypeensive drugs should not be used in such patients :
**Question:** A 40 year old male patient is suffering from type II diabetes mellitus and hypertension. Which of the following antihypertensive drugs should not be used in such patients:
A. Amlodipine
B. Ramipril
C. Enalapril
D. ACE inhibitor (e.g., Ramipril)
**Core Concept:** In patients with type II diabetes mellitus, the choice of antihypertensive therapy should consider the potential for drug-induced hypoglycemia or exacerbation of diabetes-related complications due to pharmacological interactions.
**Why the Correct Answer is Right:** D. ACE inhibitors (e.g., Ramipril) should be avoided in patients with type II diabetes due to the risk of drug-induced hypoglycemia and worsening of glycemic control. In contrast, calcium channel blockers (A, C) and beta-blockers (B) are generally considered safer options for antihypertensive therapy in these patients.
**Why Each Wrong Option is Incorrect:**
A. Calcium channel blockers (Amlodipine): These drugs primarily act by blocking calcium channels in smooth muscle cells, resulting in vasodilation and reduced blood pressure. They are considered safe in patients with type II diabetes, as they do not cause hypoglycemia or worsen glycemic control.
B. Beta-blockers (Ramipril): Beta-blockers, like Ramipril (an ACE inhibitor), can cause hypoglycemia due to their effect on insulin secretion and worsening of glycemic control in patients with type II diabetes.
C. Calcium channel blockers (Enalapril): Enalapril (an ACE inhibitor) is similar to Ramipril and carries the same risks of hypoglycemia and worsening of glycemic control as Ramipril.
**Clinical Pearl:** When selecting antihypertensive agents in patients with type II diabetes, consider the potential risks and benefits of each drug option. Choose medications with minimal risk of hypoglycemia or worsening glycemic control, such as calcium channel blockers or beta-blockers. Monitor blood glucose levels closely when initiating new antihypertensive therapy in diabetic patients.